Canagliflozin (CANA) is an antidiabetic drug of the sodium-glucose co-transporter 2 inhibitor (SGLT2i) group. CANA was reported to reduce pathological events associated with heart failure. However, the exact mechanism by which CANA positively acts on cardiac tissue requires further elucidation.
(2025). Canagliflozin Reveals a Cardioprotective Effect in Acute Myocardial Infarction Management via Modulation of WnT/ β-catenin Pathway. Cardiovascular Research Prove Journal, 9(1), -. doi: 10.21608/cvrepj.2025.438153
MLA
. "Canagliflozin Reveals a Cardioprotective Effect in Acute Myocardial Infarction Management via Modulation of WnT/ β-catenin Pathway", Cardiovascular Research Prove Journal, 9, 1, 2025, -. doi: 10.21608/cvrepj.2025.438153
HARVARD
(2025). 'Canagliflozin Reveals a Cardioprotective Effect in Acute Myocardial Infarction Management via Modulation of WnT/ β-catenin Pathway', Cardiovascular Research Prove Journal, 9(1), pp. -. doi: 10.21608/cvrepj.2025.438153
VANCOUVER
Canagliflozin Reveals a Cardioprotective Effect in Acute Myocardial Infarction Management via Modulation of WnT/ β-catenin Pathway. Cardiovascular Research Prove Journal, 2025; 9(1): -. doi: 10.21608/cvrepj.2025.438153
)
View on SCiNiTO